论文部分内容阅读
Diagnostic blood assays of cancer are fast becoming a growing area of interest, with the invention of reliable circulating tumor cells (CTCs) capture devices.Emerging evidence informs of the utility of CTCs as a potentially useful clinical cancer biomarker.This study evaluates the effectiveness of a recent platform, the ScreenCellTM device, an antibody independent filtration device that retrieves cells by means of vacuum suction and entraps them on a membrane filter for further characterization.